NEWS

Press Releases

Media Coverage

Additional Partnerships

For all media inquiries, please contact media@tempus.com

02/16/2018
- Genomic Sequencing
Tempus and the Parker Institute for Cancer Immunotherapy Work Together to Analyze Data to Help Inform Immunotherapy Treatments

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Parker Institute for Cancer Immunotherapy will work together to analyze clinical and molecular data to better determine which patients will have a positive response...
01/25/2018
- Genomic Sequencing
Tempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer Patients

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced a collaboration with NYU School of Medicine aimed at improving outcomes for patients diagnosed with pancreatic cancer. Pancreatic cancer is the third leading cause...
01/04/2018
- Genomic Sequencing
Tempus and Vanderbilt-Ingram Cancer Center Announce Data Initiative to Improve Outcomes for Cancer Patients

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients. As part of the initial research project, Tempus will use...
12/21/2017
- Clinical Trials
- Genomic Sequencing
CancerLinQ Engages Leading Technology Companies Tempus and Precision HealthAI to Accelerate Data-Driven Insights to Oncologists and the Cancer Care Community

CancerLinQ LLC and the data services companies Tempus and Precision HealthAI announced today they have entered into an agreement that will accelerate development and delivery of high-quality, de-identified clinical databases for use by CancerLinQ®, its oncologist subscribers, partners, and the broader cancer community. The agreement will also enable...
12/07/2017
- Genomic Sequencing
- Product Launch
Tempus Unveils Tempus O, a Platform to Structure and Annotate Clinical Data at Scale

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data today announced the launch of Tempus O, a groundbreaking system that collects, structures and analyzes clinical data from electronic medical records, research databases, images, and physician...
11/15/2017
- Genomic Sequencing
Tempus Announces Latest Immunotherapy Project

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, along with Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center at Hackensack Meridian HealthHackensack University Medical Center announce a new...
11/01/2017
- Clinical Trials
- Genomic Sequencing
Tempus and Sanford Health Collaborate on Personalized Medicine Initiative

Tempus, a rapidly-growing technology company focused on collecting and integrating molecular and clinical data and Sanford Health, one of the largest health system in the nation will collaborate to identify targeted therapies and clinical trials for breast cancer patients. As part of the collaboration, Sanford Health will collect...
10/19/2017
Tempus Unveils Tempus xT, 595 Gene Panel Aimed at Empowering Data-Driven Cancer Care

Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to...
09/28/2017
- Clinical Trials
- Genomic Sequencing
Tempus and the OHSU Knight Cancer Institute Collaborating on Personalized Medicine Data Initiative

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Knight Cancer Institute at OHSU in Portland, Oregon, have announced a new collaboration aimed at improving outcomes for breast, pancreatic, and prostate cancer patients. ...
09/25/2017
- Genomic Sequencing
Tempus Announces $130M Raised

Tempus announced today that it closed a $70M, Series C, round of venture funding co-led by New Enterprise Associates (NEA) and Revolution Growth. This latest round brings the two-year-old company’s total funding to $130M. Tempus has spent the last two years building a series of data pipelines...

23 24 25